Annals of internal medicine
Audio Summaries

In adults with uncontrolled hypertension, a multifaceted team-based intervention vs. enhanced usual care improved BP control at 18 mo

Aug 3, 2026

The authors aimed to determine whether a multifaceted team-based intervention could improve blood pressure (BP) control in adults with uncontrolled hypertension compared to enhanced usual care. The study found that the team-based approach significantly improved BP control after 18 months, suggesting its effectiveness in managing hypertension in this population.

In older adults, mRNA-1010 vs. a licensed standard-dose influenza vaccine reduced influenza A- or B-related ILI at a median 181 d

Aug 3, 2026

The authors investigate the efficacy of mRNA-1010 compared to a licensed standard-dose influenza vaccine in reducing influenza A- or B-related influenza-like illness (ILI) in older adults. Their findings indicate that mRNA-1010 demonstrated a significant reduction in ILI over a median follow-up period of 181 days. This study aims to assess the potential advantages of mRNA technology in influenza vaccination for older populations.

In veterans with chronic pain, a whole health team intervention reduced pain interference more than CBT or usual care at 12 mo

Aug 3, 2026

This study investigates whether a whole health team intervention is more effective than cognitive behavioral therapy (CBT) or usual care in reducing pain interference in veterans with chronic pain over a 12-month period. The findings indicate that the whole health team intervention significantly outperformed both CBT and usual care in alleviating pain interference among this population.

In noncardioembolic ischemic stroke or high-risk TIA, asundexian reduced ischemic stroke and did not increase major bleeding

Aug 3, 2026

The authors investigate whether asundexian can reduce the incidence of ischemic strokes in patients with noncardioembolic ischemic stroke or high-risk transient ischemic attacks (TIAs) without increasing the risk of major bleeding. The findings suggest that asundexian effectively lowers the risk of ischemic stroke while maintaining a safety profile regarding major bleeding events.

Economic Impact of the 2025 New Mexico Measles Outbreak: Highlighting the Cost of Efforts to Prevent Future Outbreaks

Aug 3, 2026

The authors aimed to estimate the societal economic burden of the 2025 measles outbreak in New Mexico, which included 100 confirmed cases and one death, while also assessing the costs associated with public health efforts to control the outbreak and prevent future occurrences. Their analysis revealed an overall societal cost of approximately $5.4 million, with vaccination-related activities accounting for the largest portion of expenses. The findings are intended to inform policymakers and public health stakeholders about the economic implications of vaccination efforts and outbreak preparedness.

Public Policy Approaches to Addressing Adult Obesity: A Position Paper From the American College of Physicians

Aug 3, 2026

The authors of this position paper from the American College of Physicians aim to address the rising prevalence of adult obesity in the U.S. by proposing public policy recommendations that enhance the affordability and accessibility of obesity treatments. They emphasize the need to tackle modifiable factors contributing to obesity, such as diet and physical activity, while also addressing stigma and improving healthcare providers' understanding of the condition. Additionally, the paper discusses population health strategies to promote healthier food options and reduce the availability of unhealthy processed foods.

Blood pressure-lowering drugs reduce risk for major cardiovascular events regardless of CKD G category

Aug 3, 2026

The authors investigate whether blood pressure-lowering medications can reduce the risk of major cardiovascular events across different categories of chronic kidney disease (CKD). Their findings suggest that these medications are effective in lowering cardiovascular risk regardless of CKD classification, highlighting the importance of blood pressure management in this patient population.

In symptomatic HF, sacubitril-valsartan vs. dapagliflozin and torsemide vs. furosemide did not differ for health status at 6 mo

Aug 3, 2026

This study aimed to compare the health status outcomes at six months between symptomatic heart failure patients treated with sacubitril-valsartan versus dapagliflozin, and torsemide versus furosemide. The findings indicated no significant differences in health status between the treatment groups.

In large-core ischemic stroke with onset in the past 24 h, EVT vs. medical therapy improves functional outcomes and reduces mortality at 90 d

Aug 3, 2026

The authors investigate whether endovascular thrombectomy (EVT) provides better functional outcomes and reduces mortality compared to medical therapy in patients with large-core ischemic stroke that has occurred within the past 24 hours. Their findings suggest that EVT significantly improves patient outcomes at 90 days post-treatment.

In alcohol use disorder and comorbid obesity, weekly semaglutide reduced heavy drinking days at 26 wk

Aug 3, 2026

The authors investigate whether weekly administration of semaglutide can reduce heavy drinking days in individuals with alcohol use disorder and comorbid obesity. Their findings indicate that semaglutide treatment led to a significant reduction in heavy drinking days over a 26-week period. This suggests a potential therapeutic role for semaglutide in managing alcohol use disorder in this patient population.